{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true},"limitationsAndCaveats":{"description":"Following careful evaluation of the available study data and considering the limited clinical activity observed with LTT462, the decision was made to not open the dose expansion phase of the study and the study was terminated early."},"pointOfContact":{"email":"Novartis.email@novartis.com","organization":"Novartis Pharma AG","phone":"862 778-8300","title":"Study Director"}}